A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

A-M. C. Dingemans; S. Ernst; W. Mellema; S. Burgers; J. Staal-Van den Brekel; L. E. L. Hendriks; T. J. N. Hiltermann; N. Van Walree; K. Maas; M. Youssef-ElSoud; B. Biesma; V. Van Noord; E. F. F. Smit; J. A. De langen

doi:10.1016/j.annonc.2021.08.2129

A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

A-M. C. Dingemans, S. Ernst, W. Mellema, S. Burgers, J. Staal-Van den Brekel, L. E. L. Hendriks, T. J. N. Hiltermann, N. Van Walree, K. Maas, M. Youssef-ElSoud, B. Biesma, V. Van Noord, E. F. F. Smit, J. A. De langen

Translational Immunology Groningen (TRIGR)

Onderzoeksoutput › Academic

Originele taal-2	English
Pagina's (van-tot)	S1327-S1327
Aantal pagina's	1
Tijdschrift	Annals of Oncology
Volume	32
Nummer van het tijdschrift	S5
DOI's	https://doi.org/10.1016/j.annonc.2021.08.2129
Status	Published - 2021
Evenement	Congress of the European-Society-for-Medical-Oncology (ESMO) - Duur: 16-sep.-2021 → 21-sep.-2021

Toegang tot document

10.1016/j.annonc.2021.08.2129

Handle.net

Permanente koppeling

Citeer dit

Dingemans, A.-M. C., Ernst, S., Mellema, W., Burgers, S., Staal-Van den Brekel, J., Hendriks, L. E. L., Hiltermann, T. J. N., Van Walree, N., Maas, K., Youssef-ElSoud, M., Biesma, B., Van Noord, V., Smit, E. F. F., & De langen, J. A. (2021). A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22. Annals of Oncology, 32(S5), S1327-S1327. https://doi.org/10.1016/j.annonc.2021.08.2129

@article{c9e65675a08c44758cdb4612a817d3fd,

title = "A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22",

author = "Dingemans, {A-M. C.} and S. Ernst and W. Mellema and S. Burgers and {Staal-Van den Brekel}, J. and Hendriks, {L. E. L.} and Hiltermann, {T. J. N.} and {Van Walree}, N. and K. Maas and M. Youssef-ElSoud and B. Biesma and {Van Noord}, V. and Smit, {E. F. F.} and {De langen}, {J. A.}",

year = "2021",

doi = "10.1016/j.annonc.2021.08.2129",

language = "English",

volume = "32",

pages = "S1327--S1327",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "S5",

note = "Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 16-09-2021 Through 21-09-2021",

}

Dingemans, A-MC, Ernst, S, Mellema, W, Burgers, S, Staal-Van den Brekel, J, Hendriks, LEL, Hiltermann, TJN, Van Walree, N, Maas, K, Youssef-ElSoud, M, Biesma, B, Van Noord, V, Smit, EFF & De langen, JA 2021, 'A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22', Annals of Oncology, vol. 32, nr. S5, blz. S1327-S1327. https://doi.org/10.1016/j.annonc.2021.08.2129

A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22. / Dingemans, A-M. C.; Ernst, S.; Mellema, W. et al.
In: Annals of Oncology, Vol. 32, Nr. S5, 2021, blz. S1327-S1327.

Onderzoeksoutput › Academic

TY - JOUR

T1 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC)

T2 - Congress of the European-Society-for-Medical-Oncology (ESMO)

AU - Dingemans, A-M. C.

AU - Ernst, S.

AU - Mellema, W.

AU - Burgers, S.

AU - Staal-Van den Brekel, J.

AU - Hendriks, L. E. L.

AU - Hiltermann, T. J. N.

AU - Van Walree, N.

AU - Maas, K.

AU - Youssef-ElSoud, M.

AU - Biesma, B.

AU - Van Noord, V.

AU - Smit, E. F. F.

AU - De langen, J. A.

PY - 2021

Y1 - 2021

U2 - 10.1016/j.annonc.2021.08.2129

DO - 10.1016/j.annonc.2021.08.2129

M3 - Meeting Abstract

SN - 0923-7534

VL - 32

SP - S1327-S1327

JO - Annals of Oncology

JF - Annals of Oncology

IS - S5

Y2 - 16 September 2021 through 21 September 2021

ER -

Dingemans AMC, Ernst S, Mellema W, Burgers S, Staal-Van den Brekel J, Hendriks LEL et al. A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22. Annals of Oncology. 2021;32(S5):S1327-S1327. doi: 10.1016/j.annonc.2021.08.2129